

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTANSC1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	3	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	4	MAR 31	CA/CAPplus and CASREACT patent number format for U.S. applications updated
NEWS	5	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	6	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	7	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	8	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	9	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	10	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	11	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	12	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	13	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	14	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	15	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	16	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	17	JUN 25	CA/CAPplus and USPAT databases updated with IPC reclassification data
NEWS	18	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	19	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	20	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	21	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	22	JUL 28	CA/CAPplus patent coverage enhanced
NEWS	23	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	24	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	25	JUL 28	STN Viewer performance improved
NEWS	26	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS      STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN      Welcome Banner and News Items  
NEWS IPC8       For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:28:03 ON 09 AUG 2008

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:28:45 ON 09 AUG 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES:    8 AUG 2008    HIGHEST RN 1039687-60-9

DICTIONARY FILE UPDATES:   8 AUG 2008    HIGHEST RN 1039687-60-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d saved

=> activate BART10535007/A


L1                    STR

L2                    924 SEA FILE=REGISTRY SSS FUL L1

=> d l1

L1 HAS NO ANSWERS



L1                    STR



Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\STNEXP\Queries\1156840.str



chain nodes :

14

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 16 17 18 19 20 21

chain bonds :

10-16 11-14

ring bonds :

1-2 1-6 2-3 3-4 3-7 4-5 4-9 5-6 7-8 7-10 8-9 8-13 10-11 11-12 12-13

16-17 16-21 17-18 18-19 19-20 20-21

exact/norm bonds :

3-7 4-9 7-8 7-10 8-9 8-13 10-11 10-16 11-12 11-14 12-13

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21

G1:O,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
 11:Atom 12:Atom 13:Atom 14:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom  
 21:Atom

L3 STRUCTURE UPLOADED

=> d 13

L3 HAS NO ANSWERS

L3 STR



Structure attributes must be viewed using STN Express query preparation.

=> s sss sam 13

SAMPLE SEARCH INITIATED 15:30:30 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 90 TO ITERATE

100.0% PROCESSED 90 ITERATIONS

9 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 1231 TO 2369

PROJECTED ANSWERS: 9 TO 360

L4 9 SEA SSS SAM L3

=> s sss sam 13 subset=L2

SAMPLE SUBSET SEARCH INITIATED 15:31:15 FILE 'REGISTRY'

SAMPLE SUBSET SCREEN SEARCH COMPLETED - 12 TO ITERATE

100.0% PROCESSED 12 ITERATIONS

9 ANSWERS

SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):

ONLINE \*\*COMPLETE\*\*

PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):

33 TO 447

PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):

9 TO 360

L5                    9 SEA SUB=L2 SSS SAM L3

=> s sss full l3 subset=L2

FULL SUBSET SEARCH INITIATED 15:31:49 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED -            320 TO ITERATE

100.0% PROCESSED            320 ITERATIONS

278 ANSWERS

SEARCH TIME: 00.00.01

L6                    278 SEA SUB=L2 SSS FUL L3

=> save temp bart11568840/A

ENTER L#, L# RANGE, ALL, OR (END):16

ANSWER SET L6 HAS BEEN SAVED AS 'BART11568840/A'

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

44.86

45.07

FILE 'CAPLUS' ENTERED AT 15:32:34 ON 09 AUG 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Aug 2008 VOL 149 ISS 7

FILE LAST UPDATED: 8 Aug 2008 (20080808/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l6

L7                    17 L6

=> s l7 and (ay<2004 py<2004 or pry<2004)

NUMERIC VALUE NOT VALID 'AY'

Numeric values may contain 1-8 significant figures. If range notation is used, both the beginning and the end of the range must be specified, e.g., '250-300/MW'. Expressions such as '250-/MW' are not allowed. To search for values above or below a given number, use the >, =, <, or <= operators, e.g., 'MW => 250'. Text terms cannot be used in numeric expressions. If you specify a unit, it must be dimensionally correct for that field code. To see the unit

designations for field codes in the current file, enter "DISPLAY UNIT ALL" at an arrow prompt (=>).

```
=> s 17 and (ay<2004 or py<2004 or pry<2004)
      4781086 AY<2004
      24005696 PY<2004
      4252034 PRY<2004
L8          6 L7 AND (AY<2004 OR PY<2004 OR PRY<2004)
```

```
=> s 17 and (ay<2005 or py<2005 or pry<2005)
      5106376 AY<2005
      25109025 PY<2005
      4581875 PRY<2005
L9          11 L7 AND (AY<2005 OR PY<2005 OR PRY<2005)
```

```
=> s 19
L10          17 L9
```

```
=> s 110 and (ay<2005 or py<2005 or pry<2005)
      5106376 AY<2005
      25109025 PY<2005
      4581875 PRY<2005
L11          11 L10 AND (AY<2005 OR PY<2005 OR PRY<2005)
```

```
=> d ibib abs hitstr 1-11
```

```
L11  ANSWER 1 OF 11  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:      2005:1241186  CAPLUS  Full-text
DOCUMENT NUMBER:       143:477858
TITLE:                 Preparation of substituted pyrido[3,2-b]indoles for
                        use in pharmaceutical compositions for the treatment
                        of HIV-infection
INVENTOR(S):           Kesteleyn, Bart Rudolf Romanie; Van De Vreken, Wim;
                        Kindermans, Natalie Maria Francisca; Canard, Maxime
                        Francis Jean-Marie Ghislain; Hertogs, Kurt; Bettens,
                        Eva; De Vroey, Veronique Corine Paul; Jochmans, Dirk
                        Edward Desire; Wigerinck, Piet Tom Bert Paul; Wang,
                        Jing; Tahri, Abdellah; Surleraux, Dominique Louis
                        Nestor Ghislain
PATENT ASSIGNEE(S):    Tibotec Pharmaceuticals Ltd., Ire.
SOURCE:                PCT Int. Appl., 92 pp.
                        CODEN: PIXXD2
DOCUMENT TYPE:         Patent
LANGUAGE:              English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2005110411	A1	20051124	WO 2005-EP52266	20050517 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,			

EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,  
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
MR, NE, SN, TD, TG


AU 2005244449	A1	20051124	AU 2005-244449	20050517 <--
CA 2563601	A1	20051124	CA 2005-2563601	20050517 <--
EP 1750708	A1	20070214	EP 2005-747916	20050517 <--

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,  
HR, LV, MK, YU

CN 1953751	A	20070425	CN 2005-80015688	20050517 <--
BR 2005011144	A	20071127	BR 2005-11144	20050517 <--
JP 2007538053	T	20071227	JP 2007-517256	20050517 <--
IN 2006DN06106	A	20070831	IN 2006-DN6106	20061019 <--
US 20070249655	A1	20071025	US 2006-569111	20061114 <--
MX 2006PA13316	A	20070202	MX 2006-PA13316	20061116 <--
KR 2007011588	A	20070124	KR 2006-725921	20061208 <--

PRIORITY APPLN. INFO.: EP 2004-102173 A 20040517 <--  
US 2004-102173 A 20040517 <--  
WO 2005-EP52266 W 20050517

OTHER SOURCE(S): CASREACT 143:477858; MARPAT 143:477858  
GI



AB Pyrido[3,2-b]indoles, such as I [R1 = H, CN, halogen, alkylcarbonyl, etc.; R2 = H, (hetero)alkyl, alkenyl, etc.; R3 = NO2, CN, OH, (un)substituted amino, etc.; n = 1-3; and their N-oxides, salts, stereoisomers, racemic mixts., prodrugs, esters or metabolites thereof], were prepared for therapeutic use and anti-HIV agents. Thus, pyrido[3,2-b]indole II was prepared via a five step synthetic scheme starting from the reaction of 1-acetyl-3-hydroxyindole with 4-nitroaniline. The prepared pyrido[3,2-b]indoles were tested for inhibition of HIV reverse transcriptase, for metabolism using human liver microsomal fractions and for anti-HIV activity. Thus, I and their pharmaceutical compns. are useful for the treatment of retroviral infections such as HIV infection, in particular, in the treatment of infections with multi-drug resistant retroviruses.

IT 304465-35-8P 352548-47-1P 698396-45-1P  
698396-64-4P 698396-65-5P 698396-80-4P  
698396-93-9P 698396-97-3P 698396-98-4P  
698397-05-6P 698397-11-4P 698397-15-8P  
698397-18-1P 698397-19-2P 698397-25-0P  
698397-41-0P 698397-43-2P 698397-44-3P  
698397-45-4P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of substituted pyrido[3,2-b]indoles for use in pharmaceutical compns. for the treatment of HIV-infection)


RN 304465-35-8 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-  
(CA INDEX NAME)




RN 352548-47-1 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



RN 698396-45-1 CAPLUS

CN 5H-Pyrido[3,2-b]indole-5-acetic acid, 3-cyano-1,2-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-64-4 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-bromophenyl)-2,5-dihydro-2-oxo-




(CA INDEX NAME)




RN 698396-65-5 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-bromophenyl)-2,5-dihydro-5-methyl-2-oxo- (CA INDEX NAME)




RN 698396-80-4 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-aminophenyl)-2,5-dihydro-2-oxo- (CA INDEX NAME)




RN 698396-93-9 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carboximidamide, 2,5-dihydro-N-hydroxy-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-97-3 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carboxylic acid, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-, methyl ester (CA INDEX NAME)




RN 698396-98-4 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carboxylic acid, 2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo-, methyl ester (CA INDEX NAME)




RN 698397-05-6 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1-[4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)phenyl]-1,5-dihydro-5-methyl- (CA INDEX NAME)




RN 698397-11-4 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-aminophenyl)-2,5-dihydro-5-methyl-2-oxo- (CA INDEX NAME)




RN 698397-15-8 CAPLUS

CN Benzonitrile, 4-(2,5-dihydro-2-oxo-1H-pyrido[3,2-b]indol-1-yl)- (CA INDEX NAME)




RN 698397-18-1 CAPLUS

CN Benzonitrile, 4-(2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)- (CA INDEX NAME)




RN 698397-19-2 CAPLUS

CN Benzenecarboximidamide, 4-(2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)-N-hydroxy- (CA INDEX NAME)




RN 698397-25-0 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]- (CA INDEX NAME)




RN 698397-41-0 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1-(4-acetylphenyl)-1,5-dihydro-5-methyl- (CA INDEX NAME)




RN 698397-43-2 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1-[4-(5-chloro-1,2,4-oxadiazol-3-yl)phenyl]-1,5-dihydro-5-methyl- (CA INDEX NAME)




RN 698397-44-3 CAPLUS

CN Benzonitrile, 4-(3-bromo-2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)- (CA INDEX NAME)



RN 698397-45-4 CAPLUS

CN Benzenecarbothioamide, 4-(2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)- (CA INDEX NAME)




IT 698397-13-6

RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use);  
BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)  
(preparation of substituted pyrido[3,2-b]indoles for use in pharmaceutical  
comps. for the treatment of HIV-infection)

RN 698397-13-6 CAPLUS

CN Benzoic acid, 4-(2,5-dihydro-2-oxo-1H-pyrido[3,2-b]indol-1-yl)-, ethyl  
ester (CA INDEX NAME)



IT 698396-30-4P 698396-31-5P 698396-32-6P  
698396-33-7P 698396-34-8P 698396-35-9P  
698396-36-0P 698396-37-1P 698396-38-2P  
698396-39-3P 698396-40-6P 698396-41-7P  
698396-42-8P 698396-43-9P 698396-44-0P  
698396-46-2P 698396-47-3P 698396-48-4P  
698396-49-5P 698396-50-8P 698396-51-9P  
698396-52-0P 698396-53-1P 698396-54-2P  
698396-55-3P 698396-56-4P 698396-57-5P  
698396-58-6P 698396-59-7P 698396-60-0P  
698396-61-1P 698396-62-2P 698396-63-3P  
698396-66-6P 698396-67-7P 698396-68-8P  
698396-69-9P 698396-70-2P 698396-71-3P  
698396-72-4P 698396-73-5P 698396-74-6P  
698396-75-7P 698396-76-8P 698396-77-9P  
698396-78-0P 698396-79-1P 698396-81-5P  
698396-82-6P 698396-83-7P 698396-84-8P  
698396-85-9P 698396-86-0P 698396-87-1P  
698396-88-2P 698396-89-3P 698396-90-6P  
698396-91-7P 698396-92-8P 698396-94-0P  
698396-95-1P 698396-96-2P 698396-99-5P  
698397-00-1P 698397-01-2P 698397-02-3P

698397-03-4P 698397-04-5P 698397-06-7P  
 698397-07-8P 698397-08-9P 698397-09-0P  
 698397-10-3P 698397-12-5P 698397-14-7P  
 698397-16-9P 698397-17-0P 698397-20-5P  
 698397-21-6P 698397-22-7P 698397-23-8P  
 698397-24-9P 698397-26-1P 698397-27-2P  
 698397-28-3P 698397-29-4P 698397-30-7P  
 698397-31-8P 698397-32-9P 698397-33-0P  
 698397-34-1P 698397-35-2P 698397-36-3P  
 698397-37-4P 698397-38-5P 698397-39-6P  
 698397-40-9P 698397-42-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of substituted pyrido[3,2-b]indoles for use in pharmaceutical  
 comps. for the treatment of HIV-infection)


RN 698396-30-4 CAPLUS

CN 5H-Pyrido[3,2-b]indole-5-acetamide, 3-cyano-1,2-dihydro-N-methyl-N-[2-(4-  
 morpholinyl)ethyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 698396-31-5 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-(2-methylpropyl)-1-(4-  
 nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-32-6 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-(phenylmethyl)- (CA INDEX NAME)



RN 698396-33-7 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-(2-propen-1-yl)- (CA INDEX NAME)



RN 698396-34-8 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-butyl-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)






RN 698396-35-9 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-ethyl-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-36-0 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-cyclopentyl-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-37-1 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[2-(4-morpholinyl)ethyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-38-2 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-(3-buten-1-yl)-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-39-3 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 698396-40-6 CAPLUS  
CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-[2-(1-pyrrolidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 698396-41-7 CAPLUS  
CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-[2-(1-pyrrolidinyl)ethyl]-, ethanedioate (1:1) (CA INDEX NAME)


CM 1

CRN 698396-39-3  
CMF C24 H21 N5 O3



CM 2

CRN 144-62-7  
CMF C2 H2 O4




RN 698396-42-8 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-[2-(1-pyrrolidinyl)ethyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 698396-39-3


CMF C24 H21 N5 O3



CM 2


CRN 75-75-2

CMF C H4 O3 S




RN 698396-43-9 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 698396-44-0 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-[3-(dimethylamino)propyl]-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-46-2 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-47-3 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-[3-(1-piperidiny)propyl]- (CA INDEX NAME)




RN 698396-48-4 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[4-(4-methyl-1-piperazinyl)butyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-49-5 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[4-(4-morpholinyl)butyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-50-8 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 698396-51-9 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-[4-(1-pyrrolidinyl)butyl]- (CA INDEX NAME)



RN 698396-52-0 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[3-(4-methyl-1-piperazinyl)propyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)






RN 698396-53-1 CAPLUS

CN 5H-Pyrido[3,2-b]indole-5-acetonitrile, 3-cyano-1,2-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-54-2 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[3-(4-morpholinyl)propyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-55-3 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-[4-(1-piperidinyl)butyl]- (CA INDEX NAME)




RN 698396-56-4 CAPLUS

CN 5H-Pyrido[3,2-b]indole-5-acetic acid, 3-cyano-1,2-dihydro-1-(4-nitrophenyl)-2-oxo-, ethyl ester (CA INDEX NAME)




RN 698396-57-5 CAPLUS

CN 5H-Pyrido[3,2-b]indole-5-propanenitrile, 3-cyano-1,2-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-58-6 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-[4-(dimethylamino)butyl]-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-59-7 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[2-(1H-imidazol-5-yl)ethyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-60-0 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 698396-61-1 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 698396-62-2 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 698396-63-3 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-fluorophenyl)-2,5-dihydro-2-oxo- (CA INDEX NAME)




RN 698396-66-6 CAPLUS

CN Methanimidamide, N'-[4-(3-cyano-2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)phenyl]-N,N-dimethyl- (CA INDEX NAME)




RN 698396-67-7 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-fluoro-3-nitrophenyl)-2,5-dihydro-2-oxo- (CA INDEX NAME)




RN 698396-68-8 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(3-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-69-9 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-methyl-1-(3-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-70-2 CAPLUS  
 CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-fluorophenyl)-2,5-dihydro-5-methyl-2-oxo- (CA INDEX NAME)



RN 698396-71-3 CAPLUS  
 CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-cyanophenyl)-2,5-dihydro-2-oxo- (CA INDEX NAME)




RN 698396-72-4 CAPLUS  
 CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-cyanophenyl)-2,5-dihydro-5-methyl-2-oxo- (CA INDEX NAME)




RN 698396-73-5 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-cyanophenyl)-2,5-dihydro-2-oxo-5-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 698396-74-6 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-[4-(2-furanyl)phenyl]-2,5-dihydro-5-methyl-2-oxo- (CA INDEX NAME)




RN 698396-75-7 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-cyanophenyl)-2,5-dihydro-2-oxo-5-(2-propen-1-yl)- (CA INDEX NAME)




RN 698396-76-8 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-cyanophenyl)-2,5-dihydro-5-[2-(4-morpholinyl)ethyl]-2-oxo- (CA INDEX NAME)



RN 698396-77-9 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-cyanophenyl)-2,5-dihydro-2-oxo-5-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)






RN 698396-78-0 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-[4-(5-acetyl-2-thienyl)phenyl]-  
2,5-dihydro-5-methyl-2-oxo- (CA INDEX NAME)




RN 698396-79-1 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-[4-(3,5-dimethyl-4-isoxazolyl)phenyl]-2,5-dihydro-5-methyl-2-oxo- (CA INDEX NAME)




RN 698396-81-5 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-methoxyphenyl)-5-methyl-2-oxo- (CA INDEX NAME)




RN 698396-82-6 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-methyl-2-oxo-1-[4-(3-thienyl)phenyl]- (CA INDEX NAME)




RN 698396-83-7 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-[4-(3-furanyl)phenyl]-2,5-dihydro-5-methyl-2-oxo- (CA INDEX NAME)




RN 698396-84-8 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-methyl-2-oxo-1-[4-(1H-pyrrol-1-yl)phenyl]- (CA INDEX NAME)




RN 698396-85-9 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-methyl-2-oxo-1-[4-(4H-1,2,4-triazol-4-yl)phenyl]- (CA INDEX NAME)




RN 698396-86-0 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1-(4-nitrophenyl)- (CA INDEX NAME)




RN 698396-87-1 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 3-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-1,5-dihydro-5-methyl-1-(4-nitrophenyl)- (CA INDEX NAME)




RN 698396-88-2 CAPLUS


CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-1-(4-nitrophenyl)-3-(3-pyridinyl)-  
(CA INDEX NAME)




RN 698396-89-3 CAPLUS  
CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-1-(4-nitrophenyl)- (CA INDEX  
NAME)



RN 698396-90-6 CAPLUS  
CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-(4-nitrophenyl)- (CA  
INDEX NAME)




RN 698396-91-7 CAPLUS  
CN 2H-Pyrido[3,2-b]indol-2-one, 3-bromo-1,5-dihydro-5-methyl-1-(4-  
nitrophenyl)- (CA INDEX NAME)




RN 698396-92-8 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-1-(4-nitrophenyl)-3-(2H-tetrazol-5-yl)- (CA INDEX NAME)




RN 698396-94-0 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-1,5-dihydro-5-methyl-1-(4-nitrophenyl)- (CA INDEX NAME)




RN 698396-95-1 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-(4-nitrophenyl)-3-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 698396-96-2 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 3-(2,5-dihydro-5-thioxo-1,2,4-oxadiazol-3-yl)-1,5-dihydro-5-methyl-1-(4-nitrophenyl)- (CA INDEX NAME)




RN 698396-99-5 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carboxamide, 2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698397-00-1 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carboxylic acid, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698397-01-2 CAPLUS

CN Benzamide, 4-(2,5-dihydro-2-oxo-1H-pyrido[3,2-b]indol-1-yl)-N,N-dimethyl-  
(CA INDEX NAME)




RN 698397-02-3 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-[4-[5-(phenylmethyl)-  
1,2,4-oxadiazol-3-yl]phenyl]- (CA INDEX NAME)




RN 698397-03-4 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[4-(2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-  
b]indol-1-yl)phenyl]- (CA INDEX NAME)




RN 698397-04-5 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-[4-(1,2,4-oxadiazol-3-yl)phenyl]- (CA INDEX NAME)



RN 698397-06-7 CAPLUS

CN 1,2,4-Oxadiazole-4(5H)-acetonitrile, 3-[4-(2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)phenyl]-5-oxo- (CA INDEX NAME)




RN 698397-07-8 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1-[4-(5-cyclopropyl-1,2,4-oxadiazol-3-




yl)phenyl]-1,5-dihydro-5-methyl- (CA INDEX NAME)




RN 698397-08-9 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 3-bromo-1,5-dihydro-5-methyl-1-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]- (CA INDEX NAME)




RN 698397-09-0 CAPLUS

CN Benzoic acid, 4-(3-chloro-2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)- (CA INDEX NAME)




RN 698397-10-3 CAPLUS

CN Benzonitrile, 4-[3-(2-furanyl)-2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl]- (CA INDEX NAME)




RN 698397-12-5 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carboxamide, 2,5-dihydro-N,1-bis(4-methoxyphenyl)-2-oxo- (CA INDEX NAME)




RN 698397-14-7 CAPLUS

CN Benzoic acid, 4-(2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)-, ethyl ester (CA INDEX NAME)




RN 698397-16-9 CAPLUS

CN Benzoic acid, 4-(2,5-dihydro-2-oxo-1H-pyrido[3,2-b]indol-1-yl)- (CA INDEX NAME)




RN 698397-17-0 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-1-[4-(2H-tetrazol-5-yl)phenyl]-  
(CA INDEX NAME)




RN 698397-20-5 CAPLUS

CN Benzamide, 4-(2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)- (CA  
INDEX NAME)




RN 698397-21-6 CAPLUS

CN Benzoic acid, 4-(2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)-  
(CA INDEX NAME)




RN 698397-22-7 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-1-[4-[5-(3-methoxyphenyl)-1,2,4-oxadiazol-3-yl]phenyl]-5-methyl- (CA INDEX NAME)




RN 698397-23-8 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1-[4-[5-(3-butylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]-1,5-dihydro-5-methyl- (CA INDEX NAME)




RN 698397-24-9 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1-[4-[5-(2-furanyl)-1,2,4-oxadiazol-3-yl]phenyl]-1,5-dihydro-5-methyl- (CA INDEX NAME)




RN 698397-26-1 CAPLUS

CN Benzonitrile, 4-[2-[4-(2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)phenyl]-4-thiazolyl]- (CA INDEX NAME)




RN 698397-27-2 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-[4-(4-methyl-2-thiazolyl)phenyl]- (CA INDEX NAME)




RN 698397-28-3 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-1-[4-[5-(4-methoxyphenyl)-1,2,4-oxadiazol-3-yl]phenyl]-5-methyl- (CA INDEX NAME)




RN 698397-29-4 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-[4-[5-(3-nitrophenyl)-1,2,4-oxadiazol-3-yl]phenyl]- (CA INDEX NAME)




RN 698397-30-7 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-[4-(5-propyl-1,2,4-oxadiazol-3-yl)phenyl]- (CA INDEX NAME)




RN 698397-31-8 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-[4-[5-(5-methyl-3-isoxazolyl)-1,2,4-oxadiazol-3-yl]phenyl]- (CA INDEX NAME)



RN 698397-32-9 CAPLUS


CN 2H-Pyrido[3,2-b]indol-2-one, 1-[4-[5-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl]phenyl]-1,5-dihydro-5-methyl- (CA INDEX NAME)



RN 698397-33-0 CAPLUS


CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]- (CA INDEX NAME)






RN 698397-34-1 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]- (CA INDEX NAME)




RN 698397-35-2 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-[4-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]phenyl]- (CA INDEX NAME)




RN 698397-36-3 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1-[4-(5-ethyl-1,2,4-oxadiazol-3-yl)phenyl]-  
1,5-dihydro-5-methyl- (CA INDEX NAME)




RN 698397-37-4 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1-[4-(4,5-dihydro-4-methyl-5-oxo-1,2,4-  
oxadiazol-3-yl)phenyl]-1,5-dihydro-5-methyl- (CA INDEX NAME)




RN 698397-38-5 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1-[4-(2,5-dihydro-5-thioxo-1,2,4-oxadiazol-3-  
yl)phenyl]-1,5-dihydro-5-methyl- (CA INDEX NAME)




RN 698397-39-6 CAPLUS

CN 1,2,4-Oxadiazole-5-carboxylic acid, 3-[4-(2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 698397-40-9 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1-[4-[5-(dimethylamino)-1,2,4-oxadiazol-3-yl]phenyl]-1,5-dihydro-5-methyl- (CA INDEX NAME)



RN 698397-42-1 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-1-[4-(5-isoxazolyl)phenyl]-5-methyl- (CA INDEX NAME)




IT 698397-46-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted pyrido[3,2-b]indoles for use in pharmaceutical compns. for the treatment of HIV-infection)

RN 698397-46-5 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-(3-chloropropyl)-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1241160 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 143:477857


TITLE: Preparation of benzo[4,5]furo[3,2-b]pyridin-2-ones and pyrido[3,2-b]indol-2-ones as inhibitors of HIV reverse transcriptase

INVENTOR(S): Kesteleyn, Bart Rudolf Romanie; Van De Vreken, Wim; Surleraux, Dominique Louis Nestor Ghislain; Vendeville, Sandrine Marie Helene; Raboisson, Pierre Jean-Marie Bernard; Wigerinck, Piet Tom Bert Paul; Peeters, Annick Ann


PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.

SOURCE: PCT Int. Appl., 94 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005111044	A1	20051124	WO 2005-EP52265	20050517 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1751165	A1	20070214	EP 2005-752659	20050517 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1953982	A	20070425	CN 2005-80015617	20050517 <--
BR 2005011267	A	20071127	BR 2005-11267	20050517 <--
JP 2007538052	T	20071227	JP 2007-517255	20050517 <--
IN 2006DN06230	A	20070831	IN 2006-DN6230	20061025 <--
US 20070213320	A1	20070913	US 2006-569108	20061114 <--
MX 2006PA13315	A	20070202	MX 2006-PA13315	20061116 <--
PRIORITY APPLN. INFO.:			EP 2004-102172	A 20040517 <--
			WO 2005-EP52265	W 20050517
OTHER SOURCE(S):			CASREACT 143:477857; MARPAT 143:477857	
GI				



I



II

AB Title compds. represented by the formula I [wherein R1 = H, cyano, halo, aminocarbonyl, etc.; X = bivalent radical (un)substituted amino, O, S, SO, SO2; R2 = halo, hydroxy, amino, etc.; R3 = (un)substituted Ph or (bi)cyclic aromatic heterocyclic ring system; a1:a2-a3:a4 = CH:CH-CH:CH, N:CH-CH:CH, CH:N-CH:CH, CH:CH-N:CH, CH:CH-CH:N; and the N-oxides, salts, stereoisomeric forms, racemic mixts., prodrugs, esters and metabolites thereof] were prepared as inhibitors of HIV reverse transcriptase. For example, II was provided in a multi-step synthesis starting from 2-fluoro-4-hydroxybenzonitrile. II showed

inhibition of HIV reverse transcriptase with pEC50 value of 5.5. The pharmaceutical formulations of I were also described.

IT 869789-19-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of benzo[4,5]furo[3,2-b]pyridin-2-ones and pyrido[3,2-b]indol-

2-

ones as inhibitors of HIV reverse transcriptase)

RN 869789-19-5 CAPLUS

CN Benzofuro[3,2-b]pyridine-3-carbonitrile, 1,2-dihydro-7-methoxy-4-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



IT 869789-15-1P 869789-16-2P 869789-18-4P

869789-20-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of benzo[4,5]furo[3,2-b]pyridin-2-ones and pyrido[3,2-b]indol-

2-

ones as inhibitors of HIV reverse transcriptase)


RN 869789-15-1 CAPLUS

CN Benzofuro[3,2-b]pyridine-3-carbonitrile, 1-(4-acetylphenyl)-1,2-dihydro-4-methyl-2-oxo- (CA INDEX NAME)




RN 869789-16-2 CAPLUS

CN Benzofuro[3,2-b]pyridine-3-carbonitrile, 1-(4-cyanophenyl)-1,2-dihydro-4-methyl-2-oxo- (CA INDEX NAME)




RN 869789-18-4 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo-4-phenyl- (CA INDEX NAME)



RN 869789-20-8 CAPLUS

CN Benzofuro[3,2-b]pyridine-3-carbonitrile, 1,2-dihydro-7-hydroxy-4-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



IT 304465-35-8P 352548-47-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of benzo[4,5]furo[3,2-b]pyridin-2-ones and pyrido[3,2-b]indol-

2-


ones as inhibitors of HIV reverse transcriptase)

RN 304465-35-8 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



RN 352548-47-1 CAPLUS  
 CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1241144 CAPLUS Full-text

DOCUMENT NUMBER: 144:6779

TITLE: Preparation of 1-heterocyclyl-1,5-dihydropyrido[3,2-b]indol-2-ones and analogs as antiviral agents

INVENTOR(S): Kesteleyn, Bart Rudolf Romanie; Raboisson, Pierre Jean-Marie Bernard; Surleraux, Dominique Louis Nestor Ghislain; Hache, Geerwin Yvonne Paul; Vendeville, Sandrine Marie Helene; Peeters, Annick Ann; Wigerinck, Piet Tom Bert Paul

PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.

SOURCE: PCT Int. Appl., 100 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005111047	A1	20051124	WO 2005-EP52264	20050517 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,				



LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,  
 NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,  
 SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,  
 ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,  
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
 MR, NE, SN, TD, TG  
 AU 2005243439 A1 20051124 AU 2005-243439 20050517 <--  
 CA 2564027 A1 20051124 CA 2005-2564027 20050517 <--  
 EP 1758911 A1 20070307 EP 2005-749219 20050517 <--  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,  
 HR, LV, MK, YU  
 CN 1953983 A 20070425 CN 2005-80015818 20050517 <--  
 BR 2005011175 A 20071204 BR 2005-11175 20050517 <--  
 JP 2007538051 T 20071227 JP 2007-517254 20050517 <--  
 IN 2006DN06239 A 20070831 IN 2006-DN6239 20061025 <--  
 US 20070265295 A1 20071115 US 2006-568845 20061108 <--  
 MX 2006PA13314 A 20070202 MX 2006-PA13314 20061116 <--  
 KR 2007015608 A 20070205 KR 2006-725910 20061208 <--  
 NO 2006005898 A 20070219 NO 2006-5898 20061218 <--  
 PRIORITY APPLN. INFO.: EP 2004-102171 A 20040517 <--  
 WO 2005-EP52264 W 20050517  
 OTHER SOURCE(S): CASREACT 144:6779; MARPAT 144:6779  
 GI




AB This invention relates to 1-heterocyclyl-1,5-dihydropyrido[3,2-b]indol-2- ones and analogs I [wherein R1 = H, halo, cyano, etc.; X = O, S, SO, SO2 or (un)substituted NH; a1=a2-a3=a4 = (un)substituted -CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH- or -CH=CH-CH=N-; R3 = heteroaryl, their N-oxides, salts, stereoisomeric forms, racemic mixts., prodrugs, esters and metabolites], their use as HIV inhibitors, pharmaceutical compns. containing them and processes for preparing them. For instance, N-acetyl-3-hydroxyindole underwent successive coupling reaction with 6-chloro-3-pyridinamine, deacetylation with MeOH, formylation with POCl3-DMF in the 2nd position, and cyclization with Et cyanoacetate to give II (R = H), which was methylated with MeI to give II (R = Me). II (R = H) and II (R = Me) showed antiviral activity with pEC50 of 5.6 and 6.1, resp., in the cellular assay.

IT 869958-05-4P 869958-14-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dihydropyridoindolones and analogs as antiviral agents)


RN 869958-05-4 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-methyl-1-(1-methyl-1H-indol-5-yl)-2-oxo- (CA INDEX NAME)



RN 869958-14-5 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-(1-methyl-1H-indol-5-yl)- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1241136 CAPLUS Full-text

DOCUMENT NUMBER: 143:477955

TITLE: Preparation of 1-phenyl-1,5-dihydropyrido[3,2-b]indol-2-ones and analogs as antiviral agents

INVENTOR(S): Kesteleyn, Bart Rudolf Romanie; Vendeville, Sandrine Marie Helene; Kindermans, Natalie Maria Francisca; Surleraux, Dominique Louis Nestor Ghislain; Raboisson, Pierre Jean-Marie Bernard; Wigerinck, Piet Tom Bert Paul; Peeters, Annick Ann

PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.

SOURCE: PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2005111035	A1	20051124	WO 2005-EP52263	20050517 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1751156 A1 20070214 EP 2005-747918 20050517 <--

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU

CN 1976930 A 20070606 CN 2005-80015199 20050517 <--

BR 2005011173 A 20071204 BR 2005-11173 20050517 <--

JP 2007538050 T 20071227 JP 2007-517253 20050517 <--

IN 2006DN06236 A 20070831 IN 2006-DN6236 20061025 <--

US 20070167434 A1 20070719 US 2006-568840 20061108 <--


MX 2006PA13313 A 20070202 MX 2006-PA13313 20061116 <--

PRIORITY APPLN. INFO.: EP 2004-102170 A 20040517 <--

WO 2005-EP52263 W 20050517

OTHER SOURCE(S): CASREACT 143:477955; MARPAT 143:477955

GI



AB This invention relates to 1-phenyl-1,5-dihydropyrido[3,2-b]indol-2-ones and analogs I [n = 1-3; R1 = H, halo, cyano, etc.; R3 = nitro, cyano, amino, etc.; X = O, S, SO, SO2, (un)substituted NH; a1=a2-a3=a4 = substituted -CH=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH- or -CH=CH-CH=N-, their N-oxides, salts, stereoisomeric forms, racemic mixts., prodrugs, esters and metabolites], their use as HIV inhibitors, pharmaceutical compns. containing them and processes for preparing them. For instance, N-acetyl-3-hydroxyindole underwent successive coupling reaction with 4-nitroaniline, deacetylation with MeOH, formylation with POCl3-DMF in the 2nd position, Knoevenagel condensation with Et cyanoacetate, cyclization in refluxing ethylene glycol and N-methylation with MeI, bromination with NBS and substitution with N-methylpiperazine to give II. This compound showed antiviral activity with pEC50 = 6.5 in the cellular assay.

IT 869791-85-5P 869791-87-7P 869791-98-0P 869791-99-1P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of dihydropyridoindolones and analogs as antiviral agents)


RN 869791-85-5 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 8-bromo-2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869791-87-7 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 8-amino-2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869791-98-0 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-8-methoxy-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



RN 869791-99-1 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-8-hydroxy-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




IT 869791-86-6P 869791-89-9P 869791-90-2P  
 869791-91-3P 869792-00-7P 869792-02-9P  
 869792-08-5P 869792-09-6P 869792-10-9P  
 869792-11-0P 869792-12-1P 869792-13-2P  
 869792-14-3P 869792-15-4P 869792-16-5P  
 869792-17-6P 869792-18-7P 869792-19-8P  
 869792-20-1P 869792-21-2P 869792-22-3P  
 869792-23-4P 869792-24-5P 869792-25-6P  
 869792-26-7P 869792-27-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of dihydropyridoindolones and analogs as antiviral agents)


RN 869791-86-6 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-methyl-8-(4-methyl-1-piperazinyl)-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869791-89-9 CAPLUS

CN 1H-Pyrido[3,2-b]indole-8-carboxylic acid, 3-cyano-2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo-, methyl ester (CA INDEX NAME)




RN 869791-90-2 CAPLUS

CN Acetamide, N-[3-cyano-2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo-1H-pyrido[3,2-b]indol-8-yl]-2,2,2-trifluoro- (CA INDEX NAME)




RN 869791-91-3 CAPLUS

CN 1H-Pyrido[3,2-b]indole-8-sulfonamide, 3-cyano-2,5-dihydro-N,N,5-trimethyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869792-00-7 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 8-[3-(dimethylamino)propoxy]-2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869792-02-9 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-7-hydroxy-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869792-08-5 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-cyanophenyl)-2,5-dihydro-8-hydroxy-5-methyl-2-oxo- (CA INDEX NAME)




RN 869792-09-6 CAPLUS

CN Benzofuro[3,2-b]pyridine-3-carbonitrile, 1,2-dihydro-8-methoxy-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869792-10-9 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-8-(3-morpholinylmethyl)-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



RN 869792-11-0 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-8-hydroxy-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



RN 869792-12-1 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 8-[[3-(dimethylamino)propyl]methylamino]-2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)






RN 869792-13-2 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 8-bromo-1-(4-cyanophenyl)-2,5-dihydro-5-methyl-2-oxo- (CA INDEX NAME)




RN 869792-14-3 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-methyl-8-(4-morpholinyl)-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869792-15-4 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 8-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869792-16-5 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-methyl-8-[methyl(phenylmethyl)amino]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869792-17-6 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-methyl-8-[(3-methylbutyl)amino]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869792-18-7 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 7,8-difluoro-2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869792-19-8 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 8-fluoro-2,5-dihydro-7-methoxy-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869792-20-1 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 8-[4-(2-ethoxyethyl)-1-piperazinyl]-2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869792-21-2 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 8-[1,4'-bipiperidin]-1'-yl-2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869792-22-3 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 8-[3-(diethylamino)-1-pyrrolidinyl]-2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869792-23-4 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo-8-[4-(2-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 869792-24-5 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 8-[4-(4-fluorophenyl)-1-piperazinyl]-2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869792-25-6 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5,8-dimethyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869792-26-7 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 7,8-difluoro-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869792-27-8 CAPLUS


CN Carbamic acid, [3-cyano-2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo-1H-pyrido[3,2-b]indol-8-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 869791-88-8P 869792-01-8P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of dihydropyridoindolones and analogs as antiviral agents)  
 RN 869791-88-8 CAPLUS  
 CN 1H-Pyrido[3,2-b]indole-8-carboxylic acid, 1-(4-aminophenyl)-3-cyano-2,5-dihydro-5-methyl-2-oxo-, methyl ester (CA INDEX NAME)



RN 869792-01-8 CAPLUS  
 CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-7-methoxy-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




IT 304465-35-8P 352548-47-1P 869791-97-9P  
 869792-07-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of dihydropyridoindolones and analogs as antiviral agents)


RN 304465-35-8 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-  
(CA INDEX NAME)




RN 352548-47-1 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869791-97-9 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-8-methoxy-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



RN 869792-07-4 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-cyanophenyl)-2,5-dihydro-8-methoxy-5-methyl-2-oxo- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L11 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:1241126 CAPLUS Full-text  
 DOCUMENT NUMBER: 144:6778  
 TITLE: Preparation of 1-phenyl-1,5-dihydropyrido[3,2-b]indol-2-ones and analogs as antiviral agents  
 INVENTOR(S): Kesteleyn, Bart Rudolf Romanie; Canard, Maxime Francis Jean-Marie Ghislain; Van De Vreken, Wim; Raboisson, Pierre Jean-Marie Bernard; Surleraux, Dominique Louis Nestor Ghislain; Wigerinck, Piet Tom Bert Paul  
 PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.  
 SOURCE: PCT Int. Appl., 91 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005111034	A1	20051124	WO 2005-EP52262	20050517 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1751154	A1	20070214	EP 2005-742818	20050517 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1953978	A	20070425	CN 2005-80015474	20050517 <--
BR 2005011264	A	20071127	BR 2005-11264	20050517 <--
JP 2007538049	T	20071227	JP 2007-517252	20050517 <--
IN 2006DN06228	A	20070831	IN 2006-DN6228	20061025 <--
US 20070238727	A1	20071011	US 2006-568838	20061108 <--
MX 2006PA13312	A	20070202	MX 2006-PA13312	20061116 <--
PRIORITY APPLN. INFO.:			EP 2004-102169	A 20040517 <--



OTHER SOURCE(S):  
GI

CASREACT 144:6778; MARPAT 144:6778



AB This invention relates to 1-phenyl-1,5-dihydropyrido[3,2-b]indol-2-ones and analogs I [wherein X = O, S, SO, SO<sub>2</sub>, (un)substituted NH; n = 1-3; R1 = H, halo, cyano, etc.; R3 = nitro, cyano, amino, etc., their N-oxides, salts, stereoisomeric forms, racemic mixts., prodrugs, esters and metabolites], their use as HIV inhibitors, pharmaceutical compns. containing them and processes for preparing them. For instance, N-acetyl-3- hydroxyindole underwent successive coupling reaction with 4-nitroaniline, deacetylation with MeOH, formylation with POCl<sub>3</sub>-DMF in the 2nd position, Knoevenagel condensation with Et cyanoacetate, cyclization in refluxing ethylene glycol, Mitsunobu reaction with glycidol, and ring-opening reaction with pyrrolidine to give II. This compound showed antiviral activity with pEC<sub>50</sub> = 6.6 in the cellular assay.


IT 869883-23-8P 869883-28-3P 869883-40-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of dihydropyridoindolones and analogs as antiviral agents)


RN 869883-23-8 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-28-3 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[2-hydroxy-3-(4-thiomorpholinyl)propyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



RN 869883-40-9 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-[3-(dimethylamino)-2-hydroxypropyl]-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




IT 869883-22-7P 869883-24-9P 869883-25-0P  
 869883-26-1P 869883-27-2P 869883-29-4P  
 869883-30-7P 869883-31-8P 869883-33-0P  
 869883-34-1P 869883-35-2P 869883-36-3P  
 869883-37-4P 869883-38-5P 869883-39-6P  
 869883-41-0P 869883-42-1P 869883-43-2P  
 869883-44-3P 869883-46-5P 869883-47-6P  
 869883-48-7P 869883-49-8P 869883-50-1P  
 869883-51-2P 869883-52-3P 869883-53-4P  
 869883-54-5P 869883-55-6P 869883-56-7P  
 869883-57-8P 869883-58-9P 869883-59-0P  
 869883-60-3P 869883-61-4P 869883-62-5P  
 869883-63-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of dihydropyridoindolones and analogs as antiviral agents)

RN 869883-22-7 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[2-hydroxy-3-(4-morpholinyl)propyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



RN 869883-24-9 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-[3-(diethylamino)-2-

hydroxypropyl]-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-25-0 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[2-(2-methoxyethoxy)ethyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-26-1 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[2-hydroxy-3-(4-methyl-1-piperazinyl)propyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




PAGE 2-A




RN 869883-27-2 CAPLUS  
CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-[3-(4-acetyl-1-piperazinyl)-2-hydroxypropyl]-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




PAGE 1-A



PAGE 2-A



RN 869883-29-4 CAPLUS  
CN Benzoic acid, 4-[[3-cyano-1,2-dihydro-1-(4-nitrophenyl)-2-oxo-5H-pyrido[3,2-b]indol-5-yl]methyl]- (CA INDEX NAME)




N,N,N-trimethyl-1-(4-nitrophenyl)-2-oxo-, sulfate (2:1) (CA INDEX NAME)

CM 1

CRN 869883-32-9


CMF C25 H26 N5 O4



CM 2


CRN 14808-79-8

CMF O4 S



RN 869883-34-1 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[2-hydroxy-3-[(1-methylethyl)amino]propyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-35-2 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-[3-(1,1-dioxido-4-

thiomorpholinyl)-2-hydroxypropyl]-2,5-dihydro-1-(4-nitrophenyl)-2-oxo-  
(CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 869883-36-3 CAPLUS  
CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl]-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



RN 869883-37-4 CAPLUS




CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[2-hydroxy-3-(methylamino)propyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-38-5 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[2-hydroxy-3-[(phenylmethyl)amino]propyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



RN 869883-39-6 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-[3-[(1-ethylpropyl)amino]-2-hydroxypropyl]-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



RN 869883-41-0 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-[2-(acetyloxy)-3-(1-

pyrrolidinyl)propyl]-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-42-1 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-[(4-ethyl-2-morpholinyl)methyl]-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-43-2 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[2-[(4-methoxyphenyl)methylamino]ethyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-44-3 CAPLUS  
 CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[(4-methyl-2-morpholinyl)methyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-46-5 CAPLUS  
 CN Guanidine, N-[3-[3-cyano-1,2-dihydro-1-(4-nitrophenyl)-2-oxo-5H-pyrido[3,2-b]indol-5-yl]propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CRN 869883-45-4  
CMF C22 H19 N7 O4




CM 2


CRN 76-05-1  
CMF C2 H F3 O2




RN 869883-47-6 CAPLUS  
CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-[2-[2-(1-pyrrolidinyl)ethoxy]ethyl]- (CA INDEX NAME)

PAGE 1-A







RN 869883-48-7 CAPLUS  
 CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-[2-[2-(diethylamino)ethoxy]ethyl]-  
 2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



RN 869883-49-8 CAPLUS  
 CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[2-[2-(4-  
 morpholinyl)ethoxy]ethyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)






RN 869883-50-1 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[3-[(3R)-3-hydroxy-1-pyrrolidinyl]propyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)

Absolute stereochemistry.




RN 869883-51-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[3-cyano-1,2-dihydro-1-(4-nitrophenyl)-2-oxo-5H-pyrido[3,2-b]indol-5-yl]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 869883-52-3 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[2-(3-methyl-1-piperidinyl)ethyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-53-4 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[3-(3-methyl-1-piperidinyl)propyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-54-5 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[3-(2-methyl-1-piperidinyl)propyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-55-6 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[3-[methyl(phenylmethyl)amino]propyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



RN 869883-56-7 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-[3-(4-acetyl-1-piperazinyl)propyl]-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)





RN 869883-57-8 CAPLUS  
 CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-[3-[4-(2-pyridinyl)-1-piperazinyl]propyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


NO<sub>2</sub>

RN 869883-58-9 CAPLUS  
 CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[3-(4-hydroxy-1-piperidinyl)propyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-59-0 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[3-[4-(2-hydroxyethyl)-1-piperazinyl]propyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-60-3 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-[3-[4-(4-fluorophenyl)-1-piperazinyl]propyl]-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




PAGE 1-A




RN 869883-61-4 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-[2-(2,6-dimethyl-4-morpholinyl)ethyl]-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-62-5 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-[2-[ethyl(3-methylphenyl)amino]ethyl]-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-63-6 CAPLUS  
 CN Benzofuro[3,2-b]pyridine-3-carbonitrile, 1,2-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



IT 304465-35-8P 698397-46-5P 869883-64-7P  
 869883-65-8P 869883-66-9P 869883-67-0P  
 869883-68-1P 869883-69-2P 869883-70-5P  
 869883-71-6P 869883-72-7P 869883-73-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of dihydropyridoindolones and analogs as antiviral agents)  
 RN 304465-35-8 CAPLUS  
 CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-  
 (CA INDEX NAME)




RN 698397-46-5 CAPLUS  
 CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-(3-chloropropyl)-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-64-7 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-5-(2-oxiranylmethyl)-2-oxo- (CA INDEX NAME)




RN 869883-65-8 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[2-hydroxy-3-[(2-hydroxyethyl)methylamino]propyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-66-9 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[2-(2-hydroxyethoxy)ethyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-67-0 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[2-[2-(methylsulfonyl)oxy]ethoxy]ethyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-68-1 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-(2-chloroethyl)-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



RN 869883-69-2 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-(3-hydroxypropyl)-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



RN 869883-70-5 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-[3-[(1,3-dihydro-1,3-dioxo-2H-

isoindol-2-yl)oxy]propyl]-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-71-6 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-[3-(aminooxy)propyl]-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 869883-72-7 CAPLUS

CN Carbamic acid, [[3-[3-cyano-1,2-dihydro-1-(4-nitrophenyl)-2-oxo-5H-pyrido[3,2-b]indol-5-yl]propoxy]carbonimidoyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 869883-73-8 CAPLUS

CN Benzoic acid, 4-[[3-cyano-1,2-dihydro-1-(4-nitrophenyl)-2-oxo-5H-pyrido[3,2-b]indol-5-yl]methyl]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:453214 CAPLUS Full-text

DOCUMENT NUMBER: 141:23513

TITLE: Preparation of substituted pyrido[3,2-b]indoles for use in pharmaceutical compositions for the treatment of HIV-infection

INVENTOR(S): Kesteley, Bart Rudolf Romanie; Van De Vreken, Wim; Kindermans, Natalie Maria Francisca; Canard, Maxime Francis Jean-Marie Ghislain; Hertogs, Kurt; Bettens, Eva; De Vroey Veronique, Corine Paul; Jochmans, Dirk Edward Desire

PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.

SOURCE: PCT Int. Appl., 91 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent



LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004046143	A1	20040603	WO 2003-EP50837	20031114 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2506316	A1	20040603	CA 2003-2506316	20031114 <--
AU 2003296760	A1	20040615	AU 2003-296760	20031114 <--
BR 2003016209	A	20050927	BR 2003-16209	20031114 <--
EP 1594870	A1	20051116	EP 2003-811395	20031114 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1738816	A	20060222	CN 2003-80108611	20031114 <--
JP 2006508145	T	20060309	JP 2004-552729	20031114 <--
NZ 540321	A	20070928	NZ 2003-540321	20031114 <--
IN 2005DN01500	A	20070119	IN 2005-DN1500	20050413 <--
US 20060173000	A1	20060803	US 2005-535007	20050512 <--
MX 2005PA05146	A	20050722	MX 2005-PA5146	20050513 <--
NO 2005002884	A	20050815	NO 2005-2884	20050614 <--
PRIORITY APPLN. INFO.:			EP 2002-79783	A 20021115 <--
			US 2002-434950P	P 20021220 <--
			EP 2002-7983	A 20021115 <--
			WO 2003-EP50837	W 20031114 <--

OTHER SOURCE(S): MARPAT 141:23513  
 GI



AB Pyrido[3,2-b]indoles, such as I [R1 = H, CN, halogen, carboxamide, carboxyl, etc.; R2 = H, alkyl, alkenyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, etc.; R3 = NO2, CN, NH2, OH, CO2H, CONH2, methanimidamidyl, alkoxy, acyl, etc.; n = 1, 2, 3], were prepared for therapeutic use and anti-HIV agents. Thus, pyrido[3,2-b]indole II was prepared via a five step synthetic scheme starting from 1-acetyl-3- hydroxyindole, 4-nitroaniline and Et cyanoacetate.

The prepared pyrido[3,2-b]indoles were tested for inhibition of HIV reverse transcriptase, for metabolism using human liver microsomal fractions and for anti-HIV activity.


IT 304465-35-8P 352548-47-1P 698396-45-1P  
 698396-64-4P 698396-65-5P 698396-80-4P  
 698396-93-9P 698396-97-3P 698396-98-4P  
 698397-05-6P 698397-11-4P 698397-15-8P  
 698397-18-1P 698397-19-2P 698397-25-0P  
 698397-41-0P 698397-43-2P 698397-44-3P  
 698397-45-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of substituted pyrido[3,2-b]indoles for use in pharmaceutical compns. for the treatment of HIV-infection)


RN 304465-35-8 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-  
 (CA INDEX NAME)




RN 352548-47-1 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-45-1 CAPLUS

CN 5H-Pyrido[3,2-b]indole-5-acetic acid, 3-cyano-1,2-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-64-4 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-bromophenyl)-2,5-dihydro-2-oxo-  
(CA INDEX NAME)




RN 698396-65-5 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-bromophenyl)-2,5-dihydro-5-  
methyl-2-oxo- (CA INDEX NAME)




RN 698396-80-4 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-aminophenyl)-2,5-dihydro-2-oxo-  
(CA INDEX NAME)




RN 698396-93-9 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carboximidamide, 2,5-dihydro-N-hydroxy-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-97-3 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carboxylic acid, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-, methyl ester (CA INDEX NAME)




RN 698396-98-4 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carboxylic acid, 2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo-, methyl ester (CA INDEX NAME)




RN 698397-05-6 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1-[4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)phenyl]-1,5-dihydro-5-methyl- (CA INDEX NAME)




RN 698397-11-4 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-aminophenyl)-2,5-dihydro-5-methyl-2-oxo- (CA INDEX NAME)




RN 698397-15-8 CAPLUS

CN Benzonitrile, 4-(2,5-dihydro-2-oxo-1H-pyrido[3,2-b]indol-1-yl)- (CA INDEX NAME)




RN 698397-18-1 CAPLUS

CN Benzonitrile, 4-(2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)-  
(CA INDEX NAME)




RN 698397-19-2 CAPLUS

CN Benzenecarboximidamide, 4-(2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)-N-hydroxy- (CA INDEX NAME)




RN 698397-25-0 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]- (CA INDEX NAME)




RN 698397-41-0 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1-(4-acetylphenyl)-1,5-dihydro-5-methyl- (CA INDEX NAME)




RN 698397-43-2 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1-[4-(5-chloro-1,2,4-oxadiazol-3-yl)phenyl]-1,5-dihydro-5-methyl- (CA INDEX NAME)




RN 698397-44-3 CAPLUS

CN Benzonitrile, 4-(3-bromo-2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)- (CA INDEX NAME)



RN 698397-45-4 CAPLUS

CN Benzenecarbothioamide, 4-(2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)- (CA INDEX NAME)




IT 698397-13-6

RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)  
(preparation of substituted pyrido[3,2-b]indoles for use in pharmaceutical compns. for the treatment of HIV-infection)

RN 698397-13-6 CAPLUS

CN Benzoic acid, 4-(2,5-dihydro-2-oxo-1H-pyrido[3,2-b]indol-1-yl)-, ethyl ester (CA INDEX NAME)



IT 698396-30-4P 698396-31-5P 698396-32-6P



698396-33-7P 698396-34-8P 698396-35-9P  
698396-36-0P 698396-37-1P 698396-38-2P  
698396-39-3P 698396-40-6P 698396-41-7P  
698396-42-8P 698396-43-9P 698396-44-0P  
698396-46-2P 698396-47-3P 698396-48-4P  
698396-49-5P 698396-50-8P 698396-51-9P  
698396-52-0P 698396-53-1P 698396-54-2P  
698396-55-3P 698396-56-4P 698396-57-5P  
698396-58-6P 698396-59-7P 698396-60-0P  
698396-61-1P 698396-62-2P 698396-63-3P  
698396-66-6P 698396-67-7P 698396-68-8P  
698396-69-9P 698396-70-2P 698396-71-3P  
698396-72-4P 698396-73-5P 698396-74-6P  
698396-75-7P 698396-76-8P 698396-77-9P  
698396-78-0P 698396-79-1P 698396-81-5P  
698396-82-6P 698396-83-7P 698396-84-8P  
698396-85-9P 698396-86-0P 698396-87-1P  
698396-88-2P 698396-89-3P 698396-90-6P  
698396-91-7P 698396-92-8P 698396-94-0P  
698396-95-1P 698396-96-2P 698396-99-5P  
698397-00-1P 698397-01-2P 698397-02-3P  
698397-03-4P 698397-04-5P 698397-06-7P  
698397-07-8P 698397-08-9P 698397-09-0P  
698397-10-3P 698397-12-5P 698397-14-7P  
698397-16-9P 698397-17-0P 698397-20-5P  
698397-21-6P 698397-22-7P 698397-23-8P  
698397-24-9P 698397-26-1P 698397-27-2P  
698397-28-3P 698397-29-4P 698397-30-7P  
698397-31-8P 698397-32-9P 698397-33-0P  
698397-34-1P 698397-35-2P 698397-36-3P  
698397-37-4P 698397-38-5P 698397-39-6P  
698397-40-9P 698397-42-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of substituted pyrido[3,2-b]indoles for use in pharmaceutical  
comps. for the treatment of HIV-infection)


RN 698396-30-4 CAPLUS

CN 5H-Pyrido[3,2-b]indole-5-acetamide, 3-cyano-1,2-dihydro-N-methyl-N-[2-(4-  
morpholinyl)ethyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 698396-31-5 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-(2-methylpropyl)-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-32-6 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-(phenylmethyl)- (CA INDEX NAME)




RN 698396-33-7 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-(2-propen-1-yl)- (CA INDEX NAME)




RN 698396-34-8 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-butyl-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-35-9 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-ethyl-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-36-0 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-cyclopentyl-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-37-1 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[2-(4-morpholinyl)ethyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-38-2 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-(3-buten-1-yl)-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-39-3 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 698396-40-6 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-[2-(1-pyrrolidinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 698396-41-7 CAPLUS  
 CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-[2-(1-pyrrolidinyl)ethyl]-, ethanedioate (1:1) (CA INDEX NAME)


CM 1

CRN 698396-39-3  
 CMF C24 H21 N5 O3



CM 2


CRN 144-62-7  
 CMF C2 H2 O4



RN 698396-42-8 CAPLUS  
 CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-[2-(1-pyrrolidinyl)ethyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1


CRN 698396-39-3  
 CMF C24 H21 N5 O3



CM 2


CRN 75-75-2

CMF C H4 O3 S




RN 698396-43-9 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-[2-(1-piperidiny)ethyl]- (CA INDEX NAME)




RN 698396-44-0 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-[3-(dimethylamino)propyl]-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



RN 698396-46-2 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



RN 698396-47-3 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)






RN 698396-48-4 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[4-(4-methyl-1-piperazinyl)butyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-49-5 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[4-(4-morpholinyl)butyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-50-8 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 698396-51-9 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-[4-(1-pyrrolidinyl)butyl]- (CA INDEX NAME)




RN 698396-52-0 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[3-(4-methyl-1-piperazinyl)propyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-53-1 CAPLUS

CN 5H-Pyrido[3,2-b]indole-5-acetonitrile, 3-cyano-1,2-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-54-2 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[3-(4-morpholinyl)propyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-55-3 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-[4-(1-piperidinyl)butyl]- (CA INDEX NAME)




RN 698396-56-4 CAPLUS

CN 5H-Pyrido[3,2-b]indole-5-acetic acid, 3-cyano-1,2-dihydro-1-(4-nitrophenyl)-2-oxo-, ethyl ester (CA INDEX NAME)




RN 698396-57-5 CAPLUS

CN 5H-Pyrido[3,2-b]indole-5-propanenitrile, 3-cyano-1,2-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-58-6 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-[4-(dimethylamino)butyl]-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-59-7 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-[2-(1H-imidazol-5-yl)ethyl]-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698396-60-0 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 698396-61-1 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 698396-62-2 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-5-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 698396-63-3 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-fluorophenyl)-2,5-dihydro-2-oxo- (CA INDEX NAME)




RN 698396-66-6 CAPLUS

CN Methanimidamide, N'-[4-(3-cyano-2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)phenyl]-N,N-dimethyl- (CA INDEX NAME)




RN 698396-67-7 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-fluoro-3-nitrophenyl)-2,5-dihydro-2-oxo- (CA INDEX NAME)




RN 698396-68-8 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(3-nitrophenyl)-2-oxo-  
(CA INDEX NAME)



RN 698396-69-9 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-methyl-1-(3-nitrophenyl)-2-oxo- (CA INDEX NAME)



RN 698396-70-2 CAPLUS


CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-fluorophenyl)-2,5-dihydro-5-methyl-2-oxo- (CA INDEX NAME)






RN 698396-71-3 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-cyanophenyl)-2,5-dihydro-2-oxo-  
(CA INDEX NAME)




RN 698396-72-4 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-cyanophenyl)-2,5-dihydro-5-  
methyl-2-oxo- (CA INDEX NAME)




RN 698396-73-5 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-cyanophenyl)-2,5-dihydro-2-oxo-  
5-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 698396-74-6 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-[4-(2-furanyl)phenyl]-2,5-dihydro-5-methyl-2-oxo- (CA INDEX NAME)




RN 698396-75-7 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-cyanophenyl)-2,5-dihydro-2-oxo-5-(2-propen-1-yl)- (CA INDEX NAME)




RN 698396-76-8 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-cyanophenyl)-2,5-dihydro-5-[2-(4-morpholinyl)ethyl]-2-oxo- (CA INDEX NAME)




RN 698396-77-9 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-(4-cyanophenyl)-2,5-dihydro-2-oxo-5-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 698396-78-0 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-[4-(5-acetyl-2-thienyl)phenyl]-2,5-dihydro-5-methyl-2-oxo- (CA INDEX NAME)




RN 698396-79-1 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-[4-(3,5-dimethyl-4-isoxazolyl)phenyl]-2,5-dihydro-5-methyl-2-oxo- (CA INDEX NAME)




RN 698396-81-5 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-methoxyphenyl)-5-methyl-2-oxo- (CA INDEX NAME)




RN 698396-82-6 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-methyl-2-oxo-1-[4-(3-thienyl)phenyl]- (CA INDEX NAME)




RN 698396-83-7 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 1-[4-(3-furanyl)phenyl]-2,5-dihydro-5-methyl-2-oxo- (CA INDEX NAME)




RN 698396-84-8 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-methyl-2-oxo-1-[4-(1H-pyrrol-1-yl)phenyl]- (CA INDEX NAME)




RN 698396-85-9 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-5-methyl-2-oxo-1-[4-(4H-1,2,4-triazol-4-yl)phenyl]- (CA INDEX NAME)




RN 698396-86-0 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1-(4-nitrophenyl)- (CA INDEX NAME)




RN 698396-87-1 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 3-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-1,5-dihydro-5-methyl-1-(4-nitrophenyl)- (CA INDEX NAME)




RN 698396-88-2 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-1-(4-nitrophenyl)-3-(3-pyridinyl)- (CA INDEX NAME)




RN 698396-89-3 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-1-(4-nitrophenyl)- (CA INDEX NAME)




RN 698396-90-6 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-(4-nitrophenyl)- (CA INDEX NAME)




RN 698396-91-7 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 3-bromo-1,5-dihydro-5-methyl-1-(4-nitrophenyl)- (CA INDEX NAME)




RN 698396-92-8 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-1-(4-nitrophenyl)-3-(2H-tetrazol-5-yl)- (CA INDEX NAME)



RN 698396-94-0 CAPLUS


CN 2H-Pyrido[3,2-b]indol-2-one, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-1,5-dihydro-5-methyl-1-(4-nitrophenyl)- (CA INDEX NAME)



RN 698396-95-1 CAPLUS


CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-(4-nitrophenyl)-3-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)






RN 698396-96-2 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 3-(2,5-dihydro-5-thioxo-1,2,4-oxadiazol-3-yl)-1,5-dihydro-5-methyl-1-(4-nitrophenyl)- (CA INDEX NAME)




RN 698396-99-5 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carboxamide, 2,5-dihydro-5-methyl-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698397-00-1 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carboxylic acid, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)




RN 698397-01-2 CAPLUS

CN Benzamide, 4-(2,5-dihydro-2-oxo-1H-pyrido[3,2-b]indol-1-yl)-N,N-dimethyl-  
(CA INDEX NAME)




RN 698397-02-3 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-[4-[5-(phenylmethyl)-  
1,2,4-oxadiazol-3-yl]phenyl]- (CA INDEX NAME)




RN 698397-03-4 CAPLUS

CN 4-Thiazolecarboxylic acid, 2-[4-(2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-  
b]indol-1-yl)phenyl]- (CA INDEX NAME)




RN 698397-04-5 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-[4-(1,2,4-oxadiazol-3-yl)phenyl]- (CA INDEX NAME)



RN 698397-06-7 CAPLUS


CN 1,2,4-Oxadiazole-4(5H)-acetonitrile, 3-[4-(2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)phenyl]-5-oxo- (CA INDEX NAME)



RN 698397-07-8 CAPLUS


CN 2H-Pyrido[3,2-b]indol-2-one, 1-[4-(5-cyclopropyl-1,2,4-oxadiazol-3-

yl)phenyl]-1,5-dihydro-5-methyl- (CA INDEX NAME)




RN 698397-08-9 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 3-bromo-1,5-dihydro-5-methyl-1-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]- (CA INDEX NAME)




RN 698397-09-0 CAPLUS

CN Benzoic acid, 4-(3-chloro-2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)- (CA INDEX NAME)




RN 698397-10-3 CAPLUS

CN Benzonitrile, 4-[3-(2-furanyl)-2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl]- (CA INDEX NAME)




RN 698397-12-5 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carboxamide, 2,5-dihydro-N,1-bis(4-methoxyphenyl)-2-oxo- (CA INDEX NAME)




RN 698397-14-7 CAPLUS

CN Benzoic acid, 4-(2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)-, ethyl ester (CA INDEX NAME)




RN 698397-16-9 CAPLUS

CN Benzoic acid, 4-(2,5-dihydro-2-oxo-1H-pyrido[3,2-b]indol-1-yl)- (CA INDEX NAME)




RN 698397-17-0 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-1-[4-(2H-tetrazol-5-yl)phenyl]-  
(CA INDEX NAME)




RN 698397-20-5 CAPLUS

CN Benzamide, 4-(2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)- (CA  
INDEX NAME)




RN 698397-21-6 CAPLUS

CN Benzoic acid, 4-(2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)-  
(CA INDEX NAME)




RN 698397-22-7 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-1-[4-[5-(3-methoxyphenyl)-1,2,4-oxadiazol-3-yl]phenyl]-5-methyl- (CA INDEX NAME)




RN 698397-23-8 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1-[4-[5-(3-butylphenyl)-1,2,4-oxadiazol-3-yl]phenyl]-1,5-dihydro-5-methyl- (CA INDEX NAME)




RN 698397-24-9 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1-[4-[5-(2-furanyl)-1,2,4-oxadiazol-3-yl]phenyl]-1,5-dihydro-5-methyl- (CA INDEX NAME)



RN 698397-26-1 CAPLUS


CN Benzonitrile, 4-[2-[4-(2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)phenyl]-4-thiazolyl]- (CA INDEX NAME)



RN 698397-27-2 CAPLUS


CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-[4-(4-methyl-2-thiazolyl)phenyl]- (CA INDEX NAME)






RN 698397-28-3 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-1-[4-[5-(4-methoxyphenyl)-1,2,4-oxadiazol-3-yl]phenyl]-5-methyl- (CA INDEX NAME)




RN 698397-29-4 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-[4-[5-(3-nitrophenyl)-1,2,4-oxadiazol-3-yl]phenyl]- (CA INDEX NAME)




RN 698397-30-7 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-[4-(5-propyl-1,2,4-oxadiazol-3-yl)phenyl]- (CA INDEX NAME)




RN 698397-31-8 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-[4-[5-(5-methyl-3-isoxazolyl)-1,2,4-oxadiazol-3-yl]phenyl]- (CA INDEX NAME)




RN 698397-32-9 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1-[4-[5-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-3-yl]phenyl]-1,5-dihydro-5-methyl- (CA INDEX NAME)




RN 698397-33-0 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]- (CA INDEX NAME)




RN 698397-34-1 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]- (CA INDEX NAME)




RN 698397-35-2 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-5-methyl-1-[4-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]phenyl]- (CA INDEX NAME)




RN 698397-36-3 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1-[4-(5-ethyl-1,2,4-oxadiazol-3-yl)phenyl]-  
1,5-dihydro-5-methyl- (CA INDEX NAME)




RN 698397-37-4 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1-[4-(4,5-dihydro-4-methyl-5-oxo-1,2,4-  
oxadiazol-3-yl)phenyl]-1,5-dihydro-5-methyl- (CA INDEX NAME)




RN 698397-38-5 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1-[4-(2,5-dihydro-5-thioxo-1,2,4-oxadiazol-3-  
yl)phenyl]-1,5-dihydro-5-methyl- (CA INDEX NAME)




RN 698397-39-6 CAPLUS

CN 1,2,4-Oxadiazole-5-carboxylic acid, 3-[4-(2,5-dihydro-5-methyl-2-oxo-1H-pyrido[3,2-b]indol-1-yl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 698397-40-9 CAPLUS


CN 2H-Pyrido[3,2-b]indol-2-one, 1-[4-[5-(dimethylamino)-1,2,4-oxadiazol-3-yl]phenyl]-1,5-dihydro-5-methyl- (CA INDEX NAME)



RN 698397-42-1 CAPLUS  
CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-1-[4-(5-isoxazolyl)phenyl]-5-methyl- (CA INDEX NAME)



IT 698397-46-5P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of substituted pyrido[3,2-b]indoles for use in pharmaceutical compns. for the treatment of HIV-infection)  
RN 698397-46-5 CAPLUS  
CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 5-(3-chloropropyl)-2,5-dihydro-1-(4-nitrophenyl)-2-oxo- (CA INDEX NAME)



L11 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2004:30565 CAPLUS Full-text  
DOCUMENT NUMBER: 141:243275  
TITLE: Synthesis of derivatives of a new heterocyclic system, indolo[2,3-f][1,7]naphthyridine  
AUTHOR(S): Rastorgueva, N. A.; Ryabova, S. Yu.; Lisitsa, E. A.; Alekseeva, L. M.; Granik, V. G.  
CORPORATE SOURCE: Scientific Research Institute of Organic Intermediates and Dyes, Federal State Unitary Enterprise State Scientific Center, Moscow, 123995, Russia  
SOURCE: Russian Chemical Bulletin (Translation of Izvestiya Akademii Nauk, Seriya Khimicheskaya) (2003), 52(10), 2149-2156  
CODEN: RCBUEY; ISSN: 1066-5285  
PUBLISHER: Kluwer Academic/Consultants Bureau

DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 141:243275


AB 3-(N-Aryl-N-chloroacetyl)amino-2-formylindoles were converted into 3-amino-1-aryl-2-oxo-1,2-dihydropyrido[3,2-b]indoles, which were used to synthesize derivs. of a new heterocyclic system, namely, indolo[2,3-f][1,7]naphthyridine. The structures of the resulting compds. were proved by IR and <sup>1</sup>H NMR spectroscopy and mass spectrometry.

IT 474642-19-8

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of indolonaphthyridines via conversion of corresponding aminoaryloxodihydropyridoindoles)

RN 474642-19-8 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 3-amino-1,5-dihydro-1-phenyl- (CA INDEX NAME)



IT 474089-16-2P 578697-68-4P 696647-33-3P

696647-49-1P 696647-56-0P 749920-83-0P

749920-84-1P 749920-85-2P 749920-86-3P

749920-88-5P 749920-89-6P 749920-91-0P

749920-92-1P 749920-93-2P 749920-94-3P

749920-95-4P 749920-96-5P 749920-97-6P


749920-98-7P 749921-00-4P 749921-01-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of indolonaphthyridines via conversion of corresponding aminoaryloxodihydropyridoindoles)

RN 474089-16-2 CAPLUS

CN Pyridinium, 1-(2,5-dihydro-2-oxo-1-phenyl-1H-pyrido[3,2-b]indol-3-yl)-, chloride (1:1) (CA INDEX NAME)




● Cl<sup>-</sup>


RN 578697-68-4 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1-(4-chlorophenyl)-1,5-dihydro-3-nitro- (CA INDEX NAME)







RN 696647-33-3 CAPLUS  
 CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-3-nitro-1-(4-nitrophenyl)- (CA  
 INDEX NAME)



RN 696647-49-1 CAPLUS  
 CN 2H-Pyrido[3,2-b]indol-2-one, 3-amino-1-(4-ethoxyphenyl)-1,5-dihydro- (CA  
 INDEX NAME)




RN 696647-56-0 CAPLUS  
 CN 2H-Pyrido[3,2-b]indol-2-one, 3-amino-1,5-dihydro-1-(4-nitrophenyl)- (CA  
 INDEX NAME)



RN 749920-83-0 CAPLUS


CN Pyridinium, 1-[1-(4-chlorophenyl)-2,5-dihydro-2-oxo-1H-pyrido[3,2-b]indol-3-yl]-, chloride (1:1) (CA INDEX NAME)



● Cl<sup>-</sup>

RN 749920-84-1 CAPLUS


CN Pyridinium, 1-[1-(4-ethoxyphenyl)-2,5-dihydro-2-oxo-1H-pyrido[3,2-b]indol-3-yl]-, chloride (1:1) (CA INDEX NAME)




● Cl<sup>-</sup>

RN 749920-85-2 CAPLUS


CN Pyridinium, 1-[2,5-dihydro-1-(4-nitrophenyl)-2-oxo-1H-pyrido[3,2-b]indol-3-yl]-, chloride (1:1) (CA INDEX NAME)




RN 749920-86-3 CAPLUS  
 CN 2H-Pyrido[3,2-b]indol-2-one, 3-amino-1-(4-chlorophenyl)-1,5-dihydro- (CA INDEX NAME)



RN 749920-88-5 CAPLUS  
 CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-3-nitro-1-phenyl- (CA INDEX NAME)




RN 749920-89-6 CAPLUS  
 CN 2H-Pyrido[3,2-b]indol-2-one, 1-(4-ethoxyphenyl)-1,5-dihydro-3-nitro- (CA INDEX NAME)




RN 749920-91-0 CAPLUS

CN Propanedioic acid, 2-[[[1-(4-ethoxyphenyl)-2,5-dihydro-2-oxo-1H-pyrido[3,2-b]indol-3-yl]amino]methylene]-, 1,3-diethyl ester (CA INDEX NAME)




RN 749920-92-1 CAPLUS

CN Propanedioic acid, 2-[[[1-(4-chlorophenyl)-2,5-dihydro-2-oxo-1H-pyrido[3,2-b]indol-3-yl]amino]methylene]-, 1,3-diethyl ester (CA INDEX NAME)




RN 749920-93-2 CAPLUS

CN Propanedioic acid, 2-[[[1-(4-ethoxyphenyl)-2,5-dihydro-2-oxo-1H-pyrido[3,2-b]indol-3-yl]amino]methylene]-, 1,3-diethyl ester (CA INDEX NAME)




RN 749920-94-3 CAPLUS

CN Propanedioic acid, 2-[[[2,5-dihydro-1-(4-nitrophenyl)-2-oxo-1H-pyrido[3,2-b]indol-3-yl]amino]methylene]-, 1,3-diethyl ester (CA INDEX NAME)




RN 749920-95-4 CAPLUS

CN 1H-Indolo[2,3-f][1,7]naphthyridine-2-carboxylic acid, 4,5,6,11-tetrahydro-1,5-dioxo-6-phenyl-, ethyl ester (CA INDEX NAME)




RN 749920-96-5 CAPLUS

CN 1H-Indolo[2,3-f][1,7]naphthyridine-2-carboxylic acid, 6-(4-chlorophenyl)-4,5,6,11-tetrahydro-1,5-dioxo-, ethyl ester (CA INDEX NAME)




RN 749920-97-6 CAPLUS

CN 1H-Indolo[2,3-f][1,7]naphthyridine-2-carboxylic acid, 6-(4-ethoxyphenyl)-4,5,6,11-tetrahydro-1,5-dioxo-, ethyl ester (CA INDEX NAME)




RN 749920-98-7 CAPLUS


CN 1H-Indolo[2,3-f][1,7]naphthyridine-2-carboxylic acid, 4,5,6,11-tetrahydro-6-(4-nitrophenyl)-1,5-dioxo-, ethyl ester (CA INDEX NAME)



RN 749921-00-4 CAPLUS  
 CN 5H-Indolo[2,3-f][1,7]naphthyridine-2-carboxylic acid, 1-chloro-6,11-dihydro-5-oxo-6-phenyl-, ethyl ester (CA INDEX NAME)




RN 749921-01-5 CAPLUS  
 CN 5H-Indolo[2,3-f][1,7]naphthyridine-2-carboxylic acid, 1-chloro-6-(4-chlorophenyl)-6,11-dihydro-5-oxo-, ethyl ester (CA INDEX NAME)




IT 474642-22-3P 700848-07-3P 700848-08-4P  
 749920-87-4P 749920-90-9P 749920-99-8P  
 749921-02-6P 749921-03-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of indolonaphthyridines via conversion of corresponding  
 aminoaryloxodihydropyridoindoles)

RN 474642-22-3 CAPLUS  
 CN Acetamide, N-(2,5-dihydro-2-oxo-1-phenyl-1H-pyrido[3,2-b]indol-3-yl)- (CA INDEX NAME)




RN 700848-07-3 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1,5-dihydro-1-phenyl-3-  
[(phenylmethylene)amino]- (CA INDEX NAME)




RN 700848-08-4 CAPLUS

CN 2H-Pyrido[3,2-b]indol-2-one, 1-(4-chlorophenyl)-1,5-dihydro-3-  
[(phenylmethylene)amino]- (CA INDEX NAME)



RN 749920-87-4 CAPLUS


CN Acetamide, N-[2,5-dihydro-1-(4-nitrophenyl)-2-oxo-1H-pyrido[3,2-b]indol-3-  
yl]- (CA INDEX NAME)



RN 749920-90-9 CAPLUS


CN Methanimidamide, N'-(2,5-dihydro-2-oxo-1-phenyl-1H-pyrido[3,2-b]indol-3-  
yl)-N,N-dimethyl- (CA INDEX NAME)






RN 749920-99-8 CAPLUS

CN 1H-Indolo[2,3-f][1,7]naphthyridine-1,5(4H)-dione, 6,11-dihydro-6-phenyl-  
(CA INDEX NAME)




RN 749921-02-6 CAPLUS

CN 5H-Indolo[2,3-f][1,7]naphthyridine-2-carboxylic acid, 6,11-dihydro-5-oxo-6-phenyl-1-(1-piperidinyl)-, ethyl ester (CA INDEX NAME)



RN 749921-03-7 CAPLUS

CN 5H-Indolo[2,3-f][1,7]naphthyridine-2-carboxylic acid, 6-(4-chlorophenyl)-6,11-dihydro-5-oxo-1-(1-piperidinyl)-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:483896 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 137:352993

TITLE: Synthesis and properties of [1,4]diazepino[6,5-b]indoles

AUTHOR(S): Lantsetti, N. A.; Ryabova, S. Yu.; Alekseeva, L. M.; Shashkov, A. S.; Granik, V. G.

CORPORATE SOURCE: State Scientific Center of the Russian Federation "Organic Intermediate Products and Dyes Institute" (NIOPIK), Moscow, 103787, Russia

SOURCE: Russian Chemical Bulletin (Translation of Izvestiya Akademii Nauk, Seriya Khimicheskaya) (2002) 51(3), 506-512

CODEN: RCBUEY; ISSN: 1066-5285

PUBLISHER: Kluwer Academic/Consultants Bureau

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:352993

AB 1-Aryl-2-oxo-1,2,3,6-tetrahydro[1,4]diazepino[6,5-b]indole N-oxides were synthesized based on 3-(N'-aryl-N'-chloroacetyl)amino-2-formylindoles. Deoxidn. of 2-oxo-1-phenyl-1,2,3,6-tetrahydro[1,4]diazepino[6,5-b]indole N-oxide afforded 1,2,3,6-tetrahydro- and 1,2,3,4,5,6-hexahydro[1,4]diazepino[6,5-b]indole derivs. A new approach to the synthesis of pyrido[3,2-b]indole and pyrimido[5,4-b]indole derivs. was developed.


IT 474089-16-2P 474642-19-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and properties of [1,4]diazepino[6,5-b]indoles)


RN 474089-16-2 CAPLUS

CN Pyridinium, 1-(2,5-dihydro-2-oxo-1-phenyl-1H-pyrido[3,2-b]indol-3-yl)-, chloride (1:1) (CA INDEX NAME)




● Cl<sup>-</sup>

RN 474642-19-8 CAPLUS  
CN 2H-Pyrido[3,2-b]indol-2-one, 3-amino-1,5-dihydro-1-phenyl- (CA INDEX NAME)



IT 474642-22-3P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and properties of [1,4]diazepino[6,5-b]indoles)  
RN 474642-22-3 CAPLUS  
CN Acetamide, N-(2,5-dihydro-2-oxo-1-phenyl-1H-pyrido[3,2-b]indol-3-yl)- (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2002:100282 CAPLUS [Full-text](#)  
DOCUMENT NUMBER: 137:33234  
TITLE: New approach to the functionalization of  
δ-carboline derivatives  
AUTHOR(S): Ryabova, S. Yu.; Alekseeva, L. M.; Lisitza, E. A.;  
Shashkov, A. S.; Chernyshev, V. V.; Tichomirova, G.  
B.; Goyzman, M. S.; Granik, V. G.  
CORPORATE SOURCE: Russian Federation State Scientific Center "Scientific  
Research Institute of Organic Intermediates and Dyes",  
Moscow, 103787, Russia  
SOURCE: Russian Chemical Bulletin (Translation of Izvestiya

Akademii Nauk, Seriya Khimicheskaya) (2001),  
50(8), 1449-1456  
CODEN: RCBUEY; ISSN: 1066-5285

PUBLISHER: Kluwer Academic/Consultants Bureau  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 137:33234


AB The possibility of transformation of 3-cyano-1-p-nitrophenyl- $\delta$ -carbolin-2-one into 2-amino-3-cyano-1-p-nitrophenyl-1H-pyrido[3,2-b]indole derivs. and 2-imino-3-cyano-1-p-nitrophenyl-5H-pyrido[3,2-b]indole derivs. ( $\delta$ -carboline) is demonstrated. Methylation of 1-p-nitrophenyl-2-piperidino-1H- $\delta$ -carboline followed by treatment with acetone in an alkaline medium yields 4-acetonyl-5-methyl-1,4-dihydro-5H-pyrido[3,2-b]indole derivative. The rearrangement of 2-arylimino-3-cyano-1-p-nitrophenyl-5H-pyrido[3,2-b]indoles into 2-(aryl)nitrophenylamino-3-cyano-5H-pyrido[3,2-b]indoles was accomplished on heating above the m.p. or on treatment with potassium tert-butoxide. The structures of the resulting compds. were proven by <sup>1</sup>H and <sup>13</sup>C NMR spectroscopy and x-ray diffraction anal.

IT 304465-35-8

RL: RCT (Reactant); RACT (Reactant or reagent)  
(new approach to the functionalization of  $\delta$ -carboline derivs. via methylation followed by rearrangement)

RN 304465-35-8 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-  
(CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:643354 CAPLUS Full-text

DOCUMENT NUMBER: 133:335174

TITLE: 1H-Pyrido[3,2-b]indoles. Synthesis and investigation of some their spectroscopic and chemical properties

AUTHOR(S): Ryabova, S. Yu.; Alekseeva, L. M.; Granik, B. G.

CORPORATE SOURCE: RF State Scientific Center "NIOPIK", Moscow, 103787, Russia

SOURCE: Chemistry of Heterocyclic Compounds (New York)(Translation of Khimiya Geterotsiklicheskih Soedinenii) (2000), 36(3), 301-306  
CODEN: CHCCAL; ISSN: 0009-3122

PUBLISHER: Consultants Bureau

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 133:335174

AB On boiling in CF<sub>3</sub>CO<sub>2</sub>H, 2-(2-cyanovinyl)-3-[(4-nitrophenyl)amino]indoles are cyclized into the corresponding pyrido[3,2-b]indoles through activation of the CN group. Thermal cyclization of an Et  $\alpha$ -cyano- $\beta$ -indolylacrylate occurs with participation of the more reactive CO<sub>2</sub>Et group to give the resp. 3-cyanopyrido[3,2-b]indole.

IT 304465-35-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of pyrido[3,2-b]indoles)

RN 304465-35-8 CAPLUS

CN 1H-Pyrido[3,2-b]indole-3-carbonitrile, 2,5-dihydro-1-(4-nitrophenyl)-2-oxo-  
 (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:684895 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 132:64217

TITLE: N-Aryl heterocycles via coupling reactions with arylboronic acids

AUTHOR(S): Mederski, Werner W. K. R.; Lefort, Marina; Germann, Martina; Kux, Dieter

CORPORATE SOURCE: Preclinical Pharmaceutical Research, Merck KGaA, Darmstadt, 64271, Germany

SOURCE: Tetrahedron (1999), 55(44), 12757-12770  
 CODEN: TETRAB; ISSN: 0040-4020


PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 132:64217

GI




AB Compds. having a partial 2-pyridone structure, e.g., I (R = H, CHMe<sub>2</sub>, n-Bu), or 3-pyridazinones, II (R = H, Me), can be selectively N-arylated with phenylboronic acids according to the procedure described by Chan and Lam. This procedure leads to N5-arylated imidazo[4,5-c]pyridin-4-ones, e.g., III, precursors of potent factor Xa inhibitors. In addition, the synthesis of N-aryl substituted pyrrole- and indole-2-carboxylic acid esters, e.g., IV, is described. In the indole series, this procedure offers a flexible entry in the synthesis of different 1,3-diaryl-2- carboxyindoles.

IT 253274-08-7P 253274-11-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of N-aryl heterocycles via coupling with arylboronic acids)


RN 253274-08-7 CAPLUS

CN Benzofuro[3,2-b]pyridine-3-carboxylic acid, 4-(4-ethoxyphenyl)-1,2-dihydro-1-(4-methylphenyl)-2-oxo-, ethyl ester (CA INDEX NAME)



RN 253274-11-2 CAPLUS

CN Benzofuro[3,2-b]pyridine-3-carboxylic acid, 1-(3-cyanophenyl)-4-(4-ethoxyphenyl)-1,2-dihydro-2-oxo-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT:

19

THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil stng

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

68.23

72.22

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-8.80

-8.80

FILE 'STNGUIDE' ENTERED AT 16:14:32 ON 09 AUG 2008

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Aug 1, 2008 (20080801/UP).

=> logoff y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.06

72.28

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-8.80

STN INTERNATIONAL LOGOFF AT 16:15:10 ON 09 AUG 2008